Update in the pathologic features of mature B-cell and T/NK-cell leukemias

Seminars in Diagnostic Pathology

Volumn 20, Issue 3, 2003, Pages 180-195

  Hsi, Eric D ^a   Mirza, Imran ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B CELL LEUKEMIA; CELL MATURATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LABORATORY DIAGNOSIS; MOLECULAR GENETICS; MORPHOLOGICAL TRAIT; NATURAL KILLER CELL; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T CELL LEUKEMIA; TREATMENT PLANNING;

EID: 0141540451     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-2570(03)00028-5     Document Type: Article

References (179)

1. Peterson LC, Brunning RD: Bone marrow specimen processing, in Knowles DM (ed): Neoplastic Hematopathology (ed 2). Philadelphia, PA, Lippincott Williams and Wilkins, 2001, pp 1391-1405
2. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of chronic (mature) B and T lymphoid leukemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 42:567-584, 1989
3. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
4. Jaffe ES, Harris N, Stein H, et al (eds): World Health Organization classification of tumours. Pathology of Tumours of Haematopoeitic and Lymphoid Tissues. Lyon, IARC Press, 2001
5. Criel A, Verhoef G, Vlietinck R, et al: Further characterization of morphologically defined typical and atypical CLL: A clinical. immunophenotypic, cytogenetic and prognostic study on 390 cases. Br J Haematol 97:383-391, 1997
6. Finn WG, Thangavelu M, Yelavarthi KK, et al: Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. Am J Clin Pathol 105:458-467, 1996
7. Frater JL, McCarron KF, Hammel JP, et al: Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol 116:655-664, 2001
8. Matutes E, Oscier D, Garcia-Marco J, et al: Trisomy 12 defines a group of CLL with atypical morphology: Correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 92:382-388, 1996
9. Oscier DG, Matutes E, Copplestone A, et al: Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br J Haematol 98:934-939, 1997
10. Rozman C, Montserrat E: Bone marrow biopsy in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:369-371, 1988
11. Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al: Bone marrow histologic pattern-The best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 64:1642-648, 1984
12. Moreau EJ, Matutes E, A'Hern RP, et al: Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clinical Pathol 108:378-382, 1997
13. Chevallier P, Penther D, Avet-Loiseau H, et al: CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 116:142-150, 2002
14. D'Arena G, Musto P, Cascavilla N, et al: CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chomic lymphocytic leukemia. Leuk Lymphoma 42:109-114, 2001
15. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression As novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
16. Del Poeta G, Maurillo L, Venditti A, et al: Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98:2633-2639, 2001
17. Durig J, Naschar M, Schmucker U, et al: CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 16:30-35, 2002
18. Hamblin TJ, Orchard JA, Ibbotson RE, et al: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029, 2002
19. Ibrahim S, Keating M, Do KA, et al: CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98:181-186, 2001
20. Krober A, Seiler T, Benner A, et al: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002
21. Hsi ED, Kopecky KJ, Appelbaum FR, et al: Prognostic Significance of CD38 and CD20 Expression as Assessed by Quantitative Flow Cytometry in Chronic Lymphocytic Leukemia (CLL). Br J Haematol 120:1017-1025, 2003
22. Mainou-Fowler T, Dignum H, Taylor PR, et al: Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol 118:755-761, 2002
23. Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
24. Rosenwald A, Alizadeh AA, Widhopf G, et al: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639-1647, 2001
25. Dohner H, Stilgenbauer S, Benner A, et al: Genomic alterrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
26. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
27. Lin K, Sherrington PD, Dennis M, et al: Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100:1404-1409, 2002
28. Binet JL, Auquier A, Dighiero G, et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206, 1981
29. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975
30. Oudat R, Keating MJ, Lerner S, et al: Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia 16:632-635, 2002
31. Robertson LE, Huh YO, Butler JJ, et al: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 80:29-36, 1992
32. Montserrat E, Rozman C: Bone marrow biopsy in chronic lymphocytic leukemia: A review of its prognostic importance. Blood Cells 12:315-326, 1987
33. Montserrat E, Villamor N, Reverter JC, et al: Bone marrow assessment in B-cell chronic lymphocytic leukaemia: Aspirate or biopsy? A comparative study in 258 patients. Br J Haematol 93:111-116, 1996
34. Rai KR, Han T: Prognostic factors and clinical staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 4:447-456, 1990
35. Zengin N, Kars A, Sungur A, et al: The significance of the bone marrow biopsy pattern in chronic lymphocytic leukemia: A prognostic dilemma. Am J Hematol 62:208-211, 1999
36. Kay NE, Bone ND, Tschumper RC, et al: B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 16:911-919, 2002
37. Kini AR, Kay NE, Peterson LC: Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 14:1414-1418, 2000
38. Molica S: Is it time for a reassessment of prognostic features in B-cell chronic lymphocytic leukemia? Hematol Cell Ther 41:87-93, 1999
39. Molica S: Angiogenesis in B-cell chronic lymphocytic leukemia: methods of study, clinical significance and prognostic implications. Leuk Lymphoma 42:603-607, 2001
40. Molica S, Vacca A, Ribatti D, et al: Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 100:3344-3351, 2002
41. Matutes E, Owusu-Ankomah K, Morilla R, et al: The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640-1645, 1994
42. Frater JL, Tsiftsakis EK, Hsi ED, et al: Use of novel t(11;14) and t(14;18) dual-fusion fluorescence in situ hybridization probes in the differential diagnosis of lymphomas of small lymphocytes. Diagn Mol Pathol 10:214-222, 2001
43. Chacon JI, Mollejo M, Munoz E, et al: Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 100: 1648-1654, 2002
44. Ferry JA, Yang WI, Zukerberg LR, et al: CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 105:31-37, 1996
45. Costes V, Duchayne E, Taib J, et al: Intrasinusoidal bone marrow infiltration: A common growth pattern for different lymphoma subtypes. Br J Haematol 119:916-922, 2002
46. Kent SA, Variakojis D, Peterson LC: Comparative study of marginal zone lymphoma involving bone marrow. Am J Clin Pathol 117:698-708, 2002
47. Labouyrie E, Marit G, Vial JP. et al: Intrasinusoidal bone marrow involvement by splenic lymphoma with villous lymphocytes: a helpful immunohistologic feature. Mod Pathol 10:1015-1020, 1997
48. Barry TS, Jaffe ES, Kingma DW, et al: CD5+ follicular lymphoma: a clinicopathologic study of three cases. Am J Clin Pathol 118:589-598, 2002
49. Raible MD, Hsi ED, Diaz de Leon E, et al: bcl-6 protein expression in follicle center cell lymphomas: A marker for distinguishing these lymphomas from other low grade-lymphoproliferative disorders. Am J Clin Pathol 112:101-107, 1999
50. Sen F, Lai R, Albitar M: Chronic lymphocytic leukemia with the t(14;18) and trisomy 12. Arch Pathol Lab Med 126:1543-1546, 2002
51. Foucar K, Rydell RE: Richter's syndrome in chronic lymphocytic leukemia. Cancer 46:118-134, 1980
52. Matolcsy A, Chadburn A, Knowles DM: De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 147:207-216, 1995
53. Nakamine H, Masih AS, Sanger WG, et al: Richter's syndrome with different immunoglobulin light chain types. Molecular and cytogenetic features indicate a common clonal origin. Am J Clin Pathol 97:656-663, 1992
54. Foon KA, Gale RP: Clinical transformation of chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:385-388, 1988
55. Saltman DL, Ross JA, Banks RE, et al: Molecular evidence for a single clonal origin in biphenotypic concomitant chronic lymphocytic leukemia and multiple myeloma. Blood 74:2062-2065, 1989
56. Kanzler H, Kuppers R, Helmes S, et al: Hodgkin and Reed-Sternberg-like cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: Potential precursors of Hodgkin and Reed-Stemberg cells in Hodgkin's disease. Blood 95:1023-1031, 2000
57. Momose H, Jaffe ES, Shin SS, et al: Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin's disease. Mediation by Epstein-Barr virus. Am J Surg Pathol 16:859-867, 1992
58. Schlette E, Bueso-Ramos C, Giles F, et al: Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 115:571-581, 2001
59. Wong KF, So CC, Chan JK: Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia. Am J Clin Pathol 117:246-251, 2002
60. Pugh WC, Manning JT, Butler JJ: Paraimmunoblastic variant of small lymphocytic lymphoma/leukemia. Am J Surg Pathol 12:907-917, 1988
61. Nieto LH, Lampert IA, Catovsky D: Bone marrow histological patterns in B-cell and T-cell prolymphocytic leukemia. Hematol Pathol 3:79-84, 1989
62. Kroft SH, Finn WG, Peterson LC: The pathology of the chronic lymphoid leukaemia. Blood Rev 9:234-250, 1995
63. Brito-Babapulle V, Ellis J, Matutes E, et al: Translocation t(11;14)(q13;q32) in chronic lymphoid disorders. Genes Chromo Cancer 5:158-165, 1992
64. Brito-Babapulle V, Garcia-Marco J, Maljaie SH, et al: The impact of molecular cytogenetics on chronic lymphoid leukaemia. Acta Haematol 98:175-186, 1997
65. Lens D, Coignet LJ, Brito-Babapulle V, et al: B cell prolymphocytic leukaemia (B-PLL) with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene. Leukemia 13:873-876, 1999
66. Lens D, De Schouwer PJ, Hamoudi RA, et al: p53 abnormalities in B-cell prolymphocytic leukemia. Blood 89:2015-2023, 1997
67. Lens D, Matutes E, Catovsky D, et al: Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL). Leukemia 14:427-430, 2000
68. Bouroncle BA: Thirty-five years in the progress of hairy cell leukemia. Leuk Lymphoma 14(suppl 1):1-12, 1994
69. Bouroncle BA: Leukemic reticuloendotheliosis. Blood 13: 609-630, 1958
70. Frassoldati A, Lamparelli T, Frederico M, et al: Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma 13:307-316, 1994
71. Katayama I, Li CY, Yam LT: Ultrastructural characteristics of the "hairy cells" of leukemic reticuloendotheliosis. Am J Pathol 67:361-370, 1972
72. Bartl R, Frisch B, Hill W, et al: Bone marrow histology in hairy cell leukemia. Identification of subtypes and their prognostic significance. Am J Clin Pathol 79:531-545, 1983
73. Catovsky D, O'Brien M, Melo JV, et al: Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. Semin Oncol 11:362-369, 1984
74. Diez Martin JL, Li CY, Banks PM: Blastic variant of hairy-cell leukemia. Am J Clin Pathol 87:576-583, 1987
75. Pettitt AR, Zuzel M, Cawley JC: Hairy-cell leukaemia: Biology and management. Br J Haematol 106:2-8, 1999
76. Macon WR, Kinney MC, Glick AD, et al: Marrow mast cell hyperplasia in hairy cell leukemia. Mod Pathol 6:695-698, 1993
77. Burthem J, Cawley JC: The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood 83:497-504, 1994
78. Gignac SM, Quentmeier H, Brauer S: Acid phosphatase isoenzyme profiles in acute and chronic leukemias. Leuk Lymphoma 5:293-303, 1991
79. Janckila AJ, Latham MD, Lam KW, et al: Heterogeneity of hairy cell tartrate-resistant acid phosphatase. Clin Biochem 25:437-443, 1992
80. Caligaris-Cappio F, Pizzolo G, Chilosi M, et al: Phorbol ester induces abnormal chronic lymphocytic leukemia cells to express features of hairy cell leukemia. Blood 66:1035-1042, 1985
81. D'Arena G, Musto P, Cascavilla N, et al: Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 64:275-281, 2000
82. Robbins BA, Ellison DJ, Spinosa JC, et al: Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82:1277-1287, 1993
83. Hakimian D, Tallman MS, Kiley C, et al: Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 82: 1798-1802, 1993
84. Hounieu H, Chittal SM, al Saati T, et al: Hairy cell leukemia. Diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DB A.44. Am J Clin Pathol 98:26-33, 1992
85. Hoyer JD, Li CY, Yam LT, et al: Immunohistochemical demonstration of acid phosphatase isoenzyme 5 (tartrate-resistant) in paraffin sections of hairy cell leukemia and other hematologic disorders. Am J Clin Pathol 108:308-315, 1997
86. Janckila AJ, Cardwell EM, Yam LT, et al: Hairy cell identification by immunohistochemistry of tartrate-resistant acid phosphatase. Blood 85:2839-2844, 1995
87. Wheaton S, Tallman MS, Hakimian D, et al: Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 87:1556-1560, 1996
88. Bosch F, Campo E, Jares P, et al: Increased expression of the PRAD-1/CCND1 gene in hairy cell leukemia. Br J Haematol 91:1025-1030, 1995
89. Miranda RN, Briggs RC, Kinney MC, et al: Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia. Mod Pathol 13:1308-1314, 2000
90. Sainati L, Matutes E, Mulligan S, et al: A variant form of hairy cell leukemia resistant to alpha-interferon: Clinical and phenotypic characteristics of 17 patients. Blood 76:157-162, 1990
91. Matutes E, Wotherspoon A, Brito-Babapulle V, et al: The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 15:184-186, 2001
92. Janckila AJ, Gentile PS, Yam LT: Hemopoietic inhibition in hairy cell leukemia. Am J Hematol 38:30-39, 1991
93. Schwarzmeier JD, Hilgarth M, Nguyen ST, et al: Inadequate production of hematopoietic growth factors in hairy cell leukemia: Up-regulation of interleukin 6 by recombinant IFN-alpha in vitro. Cancer Res 56:4679-4685, 1996
94. Tallman MS, Peterson LC, Hakimian D, et al: Treatment of hairy-cell leukemia: Current views. Semin Hematol 36:155-163, 1999
95. Pittaluga S, Tierens A, Dodoo YL, et al: How reliable is histologic examination of bone marrow trephine biopsy specimens for the staging of non-Hodgkin lymphoma? A study of hairy cell leukemia and mantle cell lymphoma involvement of the bone marrow trephine specimen by histologic, immunohistochemical, and polymerase chain reaction techniques. Am J Clin Pathol 111:179-184, 1999
96. Elenitoba-Johnson KS, Bohling SD, Jenson SD, et al: Fluorescence PCR quantification of cyclin D1 expression. J Mol Diagn 4:90-96, 2002
97. Spech K, Kremer M, Muller U, et al: Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin section. Clin Cancer Res 8:2902-2911, 2002
98. Greer JP, Kinney MC, Loughran TP Jr: T cell and NK cell lymphoproliferative disorders. Hematology (Am Soc Hematol Educ Program): 259-281, 2001
99. Lamy T, Loughran TP Jr: Current concepts: Large granular lymphocyte leukemia. Blood Rev 13:230-240, 1999
100. Lima M, Almeida J, Santos AH, et al: Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease. Am J Pathol 159:1861-1868, 2001
101. Loughran TP Jr: Clonal diseases of large granular lymphocytes. Blood 82:1-14, 1993
102. Loughran TP Jr, Kadin ME, Starkebaum G, et al: Leukemia of large granular lymphocytes: Association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med 102:169-175, 1985
103. Perzova R, Loughran TP Jr: Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br J Haematol 97:123-126, 1997
104. Semenzato G, Zambello R, Starkebaum G, et al: The lymphoproliferative disease of granular lymphocytes: Updated criteria for diagnosis. Blood 89:256-260, 1997
105. Beck R, Stahl S, Theil KS, et al: Flow cytometric diagnosis of peripheral T-cell leukemias (TCLs) using VBeta family specific antibodies. Mod Pathol 16:226A(abstr), 2003
106. Evans HL, Burks E, Viswanatha D, et al: Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocyte leukemia. Hum Pathol 31:1266-1273, 2000
107. Morice WG, Kurtin PJ, Tefferi A, et al: Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood 99:268-274, 2002
108. Wong KF, Chan JC, Liu HS, et al: Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia: Report of two cases and review of the literature. Br J Haematol 116:598-600, 2002
109. Lamy T, Liu JH, Landowski TH, et al: Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood 92:4771-4777, 1998
110. Imamura N, Kusunoki Y, Kawa-Ha K, et al: Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol 75:49-59, 1990
111. Jaffe ES, Chan JK, Su IJ, et al: Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20:103-111, 1996
112. Lanier LL, Chang C, Spits H, et al: Expression of cytoplasmic CD3 epsilon proteins in activated human adult natural killer (NK) cells and CD3 gamma, delta, epsilon complexes in fetal NK cells. Implications for the relationship of NK and T lymphocytes. J Immunol 149:1876-1880, 1992
113. Rabbani GR, Phyliky RL, Tefferi A: A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol 106:960-966, 1999
114. Chan JK, Sin VC, Wong KF, et al: Nonnasal lymphoma expressing the natural killer cell marker CD56: A clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 89:4501-4513, 1997
115. DiGiuseppe JA, Louie DC, Williams JE, et al: Blastic natural killer cell leukemia/lymphoma: A clinicopathologic study. Am J Surg Pathol 21:1223-1230, 1997
116. Falcao RP, Garcia AB, Marques MG, et al: Blastic CD4 NK cell leukemia/lymphoma: A distinct clinical entity. Leuk Res 26:803-807, 2002
117. Leroux D, Mugneret F, Callanan M, et al: CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: A study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood 99:4154-4159, 2002
118. Rakozy CK, Mohamed AN, Vo TD, et al: CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically, cytogenetically, and clinically diverse. Am J Clin Pathol 116:168-176, 2001
119. Bartlett NL, Longo DL: T-small lymphocyte disorders. Semin Hematol 36:164-170, 1999
120. Garand R, Goasguen J, Brizard A, et al: Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d'Hematologie Cellulaire. Br J Haematol 103:488-494, 1998
121. Matutes E, Brito-Babapulle V, Swansbury J, et al: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78:3269-3274, 1991
122. Matutes E, Garcia TJ, O'Brien M, et al: The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol 64:111-124, 1986
123. Pawson R, Schulz TF, Matutes E, et al: The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia 11: 1305-1311, 1997
124. Pawson R, Matutes E, Brito-Babapulle V, et al: Sezary cell leukaemia: A distinct T cell disorder or a variant form of T prolymphocytic leukaemia? Leukemia 11:1009-1013, 1997
125. Hoyer JD, Ross CW, Li CY, et al: True T-cell chronic lymphocytic leukemia: A morphologic and immunophenotypic study of 25 cases. Blood 86:1163-1169, 1995
126. Matutes E: Mature T-cell Leukemias and leukemia/lymphoma syndromes: Review of our experience in 175 cases. Leuk Lymphoma 4:81-91, 1991
127. Sugimoto T, Imoto S, Matsuo Y, et al: T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype. Ann Hematol 80:749-751, 2001
128. Dearden CE, Matutes E, Cazin B, et al: High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98:1721-1726, 2001
129. Ginaldi L, De Martinis M, Matutes E, et al: Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22:185-191, 1998
130. Tuset E, Matutes E, Brito-Babapulle V, et al: Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia. Leuk Lymphoma 42:1379-1383, 2001
131. Brito-Babapulle V, Catovsky D: Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 55:1-9, 1991
132. Gritti C, Dastot H, Soulier J, et al: Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood 92:368-373, 1998
133. Marc-Henri S: Transgenic models of T-Cell prolymphocytic leukemia. Hematologica 84:64-66, 1999
134. Virgilio L, Lazzeri C, Bichi R, et al: Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA 95:3885-3889, 1998
135. Hetet G, et al: Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia. Hematol J 1:42-47, 2000
136. Salomon-Nguyen F, Brizard F, Le Coniat M, et al: Abnormalities of the short arm of chromosome 12 in T cell prolymphocytic leukemia. Leukemia 12:972-975, 1998
137. Stilgenbauer S, Schaffner C, Litterst A, et al: Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 3:1155-1159, 1997
138. Taylor AM, Metcalfe JA, Thick J, et al: Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423-438, 1996
139. Thick J, Mak YF, Metcalfe J, et al: A gene on chromosome Xq28 associated with T-cell prolymphocytic leukemia in two patients with ataxia telangiectasia. Leukemia 8:564-573, 1994
140. Maljaei SH, Brito-Babapulle V, Hiorns LR, et al: Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet 103:110-116, 1998
141. Kojima K, Kobayashi H, Imoto S, et al: 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia. Int J Hematol 68:291-296, 1998
142. Kingreen D, Siegert W: Chronic lymphatic leukemias of T and NK cell type. Leukemia 11(suppl 2):S46-49, 1997
143. Cheung MM, Chan JK, Wong KF: Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol 40:221-232, 2003
144. Kwong YL, Chan AC, Liang RH: Natural killer cell lymphoma/leukemia: Pathology and treatment. Hematol Oncol 15:71-79, 1997
145. Foucar K: Chronic lymphoid leukemias and lymphoproliferative disorders. Mod Pathol 12:141-150, 1999
146. Chan JK: Natural Killer Cell Neoplasms. Anat Pathol 3:77-145, 1998
147. Mori N, Yamashita Y, Tsuzuki T, et al: Lymphomatous features of aggressive NK cell leukaemia/lymphoma with massive necrosis, haemophagocytosis and EB virus infection. Histopathology 37:363-371, 2000
148. Ohno Y, Amakawa R, Fukuhara S, et al: Acute transformation of chronic large granular lymphocyte leukemia associated with additional chromosome abnormality. Cancer 64:63-67, 1989
149. Oshimi K: Lymphoproliferative disorders of natural killer cells. Int J Hematol 63:279-290, 1996
150. Oshimi K, Yamada O, Kaneko T, et al: Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia 7:782-788, 1993
151. Quintanilla-Martinez L, Jaffe ES: Commentary: aggressive NK cell lymphomas: insights into the spectrum of NK cell derived malignancies. Histopathology 37:372-374, 2000
152. Soler J, Bordes R, Ortuno F, et al: Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma. Br J Haematol 86:659-662, 1994
153. Gelb AB, van de RM, Regula DP, Jr., et al: Epstein-Barr virus-associated natural killer-large granular lymphocyte leukemia. Hum Pathol 25:953-960, 1994
154. Siu LL, Wong KF, Chan JK, et al: Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 155:1419-1425, 1999
155. Wong KF, Zhang YM, Chan JK: Cytogenetic abnormalities in natural killer cell lymphoma/leukaemia - Is there a consistent pattern? Leuk Lymphoma 34:241-250, 1999
156. Tefferi A, Li CY, Witzig TE, et al: Chronic natural killer cell lymphocytosis: A descriptive clinical study. Blood 84:2721-2725, 1994
157. Ferreira OC J, Planelles V, Rosenblatt JD: Human T-cell leukemia viruses: epidemiology, biology, and pathogenesis. Blood Rev 11:91-104, 1997
158. Fouchard N, Mahe A, Huerre M, et al: Cutaneous T cell lymphomasmycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: A clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases. Leukemia 12:578-585, 1998
159. Ohshima K, Suzumiya J, Sato K, et al: Nodal T-cell lymphoma in an HTLV-I-endemic area: proviral HTLV-I DNA, histological classification and clinical evaluation. Br J Haematol 101:703-711, 1998
160. Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79:428-437, 1991
161. Yamaguchi K: Human T-lymphotropic virus type 1 in Japan. Lancet 343:213-216, 1994
162. Franchini G: Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood 86:3619-3639, 1995
163. Jaffe ES, Blattner WA, Blayney DW, et al: The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Human T-cell leukemia/lymphoma virus-associated lymphoid malignancies. Am J Surg Pathol 8:263-275, 1984
164. Uchiyama T: Adult T-cell leukemia. Blood Rev 2:232-238, 1988
165. Ogata M, Ogata Y, Kohno K, et al: Eosinophilia associated with adult T-cell leukemia: role of interleukin 5 and granulocytemacrophage colony-stimulating factor. Am J Hematol 59:242-245, 1998
166. Niitsu Y, Urushizaki Y, Koshida Y, et al: Expression of TGF-beta gene in adult T cell leukemia. Blood 71:263-266, 1988
167. Wano Y, Hattori T, Matsuoka M, et al: Interleukin 1 gene expression in adult T cell leukemia. J Clin Invest 80:911-916, 1987
168. Watanabe T, Yamaguchi K, Takatsuki K, et al: Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be trans-activated by HTLV-1 tax gene. J Exp Med 172:759-765, 1990
169. Nosaka K, Miyamoto T, Sakai T, et al: Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 99:634-640, 2002
170. Tsukasaki K, Imaizumi Y, Tawara M, et al: Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV-1 genotype. Br J Haematol 105:369-375, 1999
171. Takeshita M, Akamatsu M, Ohshima K, et al: CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathology 26:539-546, 1995
172. Ohshima K, Mukai Y, Shiraki H, et al: Clonal integration and expression of human T-cell lymphotropic virus type I in carriers detected by polymerase chain reaction and inverse PCR. Am J Hematol 54:306-312, 1997
173. Chan JK: Peripheral T-cell and NK-cell neoplasms: an integrated approach to diagnosis. Mod Pathol 12:177-199, 1999
174. Itoyama T, Chaganti RS, Yamada Y, et al: Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: A study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 97:3612-3620, 2001
175. Tsukasaki K: Genetic instability of adult T-cell leukemia/lymphoma by comparative genomic hybridization analysis. J Clin Immunol 22:57-63, 2002
176. Mortreux F, Gabet AS, Wattel E: Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia 17:26-38, 2003
177. Kamihira S, Yamada Y, Hirakata Y, et al: Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: Survivin is an important determinant for prognosis. Br J Haematol 114:63-69, 2001
178. Nakayama K: Survivin is an important determinant for prognosis in adult T-cell leukemia: A novel biomarker in practical Hematooncology. Leuk Lymphoma 43:2249-2255, 2002
179. Sakamoto Y, Kawachi Y, Uchida T, et al: Adult T-cell leukaemia/lymphoma featuring a large granular lymphocyte leukaemia morphologically. Br J Haematol 86:383-385, 1994